Significant reductions in body weight are observed with 3.0 mg and 4.5 mg dulaglutide, doses which have been recently approved for people living with T2DM who are taking metformin but experiencing inadequate glycemic control [66, 119]
Investigated for angiogenesis (new vessel growth)
Chatelain P, Clayton P, Quinteiro S, Colle M, Cicognani A, Weill J et al
These are highly addictive, and as many as 1 in 4 people who are treated long-term with these drugs experience opioid addiction, per the CDC
and/or Imported or manufactured in Australia as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989
BPC-157 demonstrates chondroprotective effects in multiple studies, potentially slowing cartilage breakdown while supporting repair